iRadimed Corporation $IRMD Shares Newly Purchased by Kings Path Partners LLC

Kings Path Partners LLC bought a new position in shares of iRadimed Corporation (NASDAQ:IRMD) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 6,840 shares of the medical equipment provider’s stock, valued at approximately $590,000. Kings Path Partners LLC owned 0.05% of iRadimed at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its stake in shares of iRadimed by 49.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,643 shares of the medical equipment provider’s stock valued at $142,000 after acquiring an additional 545 shares during the last quarter. IFP Advisors Inc boosted its stake in iRadimed by 308.4% during the 3rd quarter. IFP Advisors Inc now owns 2,324 shares of the medical equipment provider’s stock worth $200,000 after acquiring an additional 1,755 shares during the last quarter. Davidson Capital Management Inc. boosted its stake in iRadimed by 11.2% during the 3rd quarter. Davidson Capital Management Inc. now owns 63,017 shares of the medical equipment provider’s stock worth $5,433,000 after acquiring an additional 6,333 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in iRadimed during the 2nd quarter worth approximately $28,000. Finally, NewEdge Advisors LLC grew its holdings in iRadimed by 46.9% during the second quarter. NewEdge Advisors LLC now owns 25,254 shares of the medical equipment provider’s stock valued at $2,413,000 after purchasing an additional 8,063 shares during the period. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IRMD has been the subject of several recent analyst reports. Needham & Company LLC assumed coverage on shares of iRadimed in a research note on Tuesday, September 22nd. They issued a “hold” rating for the company. Weiss Ratings raised shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 16th. Finally, Wall Street Zen lowered shares of iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, iRadimed presently has an average rating of “Moderate Buy” and an average price target of $120.00.

Insider Buying and Selling at iRadimed

In other news, Director Monty K. Allen sold 1,419 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total transaction of $122,615.79. Following the completion of the sale, the director owned 19,581 shares of the company’s stock, valued at $1,691,994.21. This represents a 6.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 34.60% of the stock is owned by company insiders.

iRadimed Price Performance

Shares of iRadimed stock opened at $87.81 on Thursday. The company has a market capitalization of $1.12 billion, a P/E ratio of 49.30 and a beta of 0.91. The business has a 50-day moving average of $86.03 and a two-hundred day moving average of $90.19. iRadimed Corporation has a 1 year low of $75.58 and a 1 year high of $107.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%. The business had revenue of $20.47 million for the quarter, compared to analysts’ expectations of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, equities analysts anticipate that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 28th. Stockholders of record on Friday, August 14th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, August 14th. iRadimed’s dividend payout ratio is 44.69%.

iRadimed Profile

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.